The Ropinirole Hydrochloride is a non-ergoline dopamine agonist with high relative specificity and full intrinsic activity at the D2 and D3 dopamine receptor subtypes. This action in humans correlates with treatment for Parkinson’s disease due to stimulation of postsynaptic dopamine D2-type receptors. Ropinirole Hydrochloride after oral administration shows a lesser bioavailability up to 55% and biological half life of 4 to 6 hours. So, present investigation deals with formulation and evaluation of buccal tablet of Ropinirole Hydrochloride. Ropinirole Hydrochloride buccal tablets were prepared by wet granulation method using Polycarbophil and HPMC K15M as mucoadhesive polymers. A 32 full factorial design was applied to investigate the combined effect of concentration of Polycarbophil (X1) and concentration of HPMC K15M (X2). Results of the multiple regression analysis revealed that the independent variables significantly affected the dependent variables (Q7(%), Mucoadhesive strength (gm) and Swelling index). An optimized formulation F6 was found to have good mucoadhesive strength 6.805 ± 0.12 gm, swelling index 106.00 ± 0.03 after 8 hr; mucoadhesive residence time was found to be more than 8 hr and cumulative percentage drug release 98.44 ± 1.47 within 8 hr. Release kinetic model studies indicated that optimized batch followed diffusive mechanism with Zero order release kinetics.
Loading....